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Background: In many developed countries, the economic crisis started in 2008 producing a serious contraction of
the financial resources spent on healthcare. Identifying which individuals will require more resources and the
moment in their lives these resources have to be allocated becomes essential. It is well known that a small number
of individuals with complex healthcare needs consume a high percentage of health expenditures. Conversely, little
is known on how morbidity evolves throughout life. The aim of this study is to introduce a longitudinal perspective
to chronic disease management.
Methods: Data used relate to the population of the county of Baix Empordà in Catalonia for the period 2004–2007
(average population was N = 88,858). The database included individual information on morbidity, resource consumption,
costs and activity records. The population was classified using the Clinical Risk Groups (CRG) model. Future morbidity
evolution was simulated under different assumptions using a stationary Markov chain. We obtained morbidity patterns
for the lifetime and the distribution function of the random variable lifetime costs. Individual information on acute
episodes, chronic conditions and multimorbidity patterns were included in the model.
Results: The probability of having a specific health status in the future (healthy, acute process or different combinations
of chronic illness) and the distribution function of healthcare costs for the individual lifetime were obtained for
the sample population. The mean lifetime cost for women was €111,936, a third higher than for men, at €81,566
(all amounts calculated in 2007 Euros). Healthy life expectancy at birth for females was 46.99, lower than for
males (50.22). Females also spent 28.41 years of life suffering from some type of chronic disease, a longer period
than men (21.9).
Conclusions: Future morbidity and whole population costs can be reasonably predicted, combining stochastic
microsimulation with a morbidity classification system. Potential ways of efficiency arose by introducing a time
perspective to chronic disease management.
Keywords: Lifetime healthcare costs, Chronic disease, Clinical Risk Groups, Markov ChainBackground
In many developed countries, the economic crisis started
in 2008 producing a serious contraction of the financial
resources spent on healthcare. Moreover, demographic
development in recent decades has resulted in older
populations which require more resources and may
generate higher expenditures [1,2]. This unfavourable
context increases the concern for refining cost estimates* Correspondence: marc.carrerasp@udg.edu
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reproduction in any medium, provided the orand resource allocation [3]. Under such a scenario,
identifying which individuals will require more resources
and the moment in their lives these resources have to
be allocated becomes essential.
It is well known that a small number of individuals with
complex healthcare needs consume a high percentage of
health expenditures [4,5]. Furthermore, for demographic
reasons, from the decade of 90s, healthcare systems were
faced with an increasing impact of chronic disease and
multimorbidity. As a response, integrated practice and
chronic disease management arose as a first effort for
maximizing efficiency. The stratification of the population
according to their risks is a fundamental part of suchl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conditions the key elements for the allocation of re-
sources [6,7].
Conversely, a little is known on how morbidity evolves
throughout life. Although recent studies suggest the
importance of adopting a life cycle perspective [8], research
in health economics has only started to consider how life
conditions observed at a specific point in time influence
health in the future [9-11]. A sound knowledge on how
individual and policy decisions influences transitions
between health states during life, especially in the early
years of life, could bring new opportunities for maximizing
effectiveness and avoiding costs.
According to the literature, healthcare costs and uti-
lization over the life time can be obtained from cross
sectional studies. For example, risk assessment models
obtain the whole population characteristics by mixing
different cohorts at a point in time [12]. However, the
life history of a particular individual or the variability
among individuals included in the same age-gender cell
is not disclosed in cross-sectional studies.
The alternative is the longitudinal analysis. The Canadian
population health model POHEM provides risk assessment
throughout the life span for people with specific chronic
diseases. e.g. different types of cancer, osteoarthritis,
acute myocardial infarction, diabetes and for disease
risk factors such as obesity and physical inactivity [13].
Longitudinal studies occasionally include costs, which
can be related to the economic evaluation of specific
technologies [14]. Other longitudinal studies simulate
future expenditures for a particular cohort using specific
mortality and population projections [1,2]. The work of
Alemayehu and Warner is particularly original, which
models cross-sectional expenditures under the mortality
experience obtained from a period life table [15]. More-
over, Forget et al. apply Markov modelling to potential
future expenditures under a cost categories transition
scheme [3]. Unfortunately, any of the above models
consider a comprehensive perspective for the individual
morbidity or health state. Only the population model
POPMOD develops a multi-state model for two dependent
interacting disease conditions and mortality [16].
Recent studies go further by proposing a joint analysis
for the main chronic diseases [17,18]. Our work aims to
follow this approach, but from a different perspective.
Thinking in how actual health conditions and decisions
can affect health in the future, we improved the article
of Forget et al. [3], including health states in the simula-
tion. Individual information on acute episodes, chronic
conditions and multimorbidity has been summarized for
a specific population using a classification system for
risk-adjustment population-based payment: Clinical Risk
Groups (CRG) [19]. We obtained morbidity patterns for
the lifetime and the distribution function of the randomvariable lifetime costs, considering age and gender, but
including at the same time chronic conditions and
multimorbidity.
A number of studies describe health states and con-
sumption patterns by gender [20,21], at different moments
of life [22-24], or for a specific chronic disease [13].
However, with few exceptions [25], it is difficult to find
studies that describe a complete pattern for the whole
life. In this article we try to fill this gap. The aim of this
study is to introduce a longitudinal perspective to chronic
disease management. From a public health point of
view, a sound knowledge on health states transitions
would benefit healthcare planners, which could promote
prevention and actions over specific groups of population
at risk. Moreover, healthcare providers involved in inte-
grated practice and chronic disease management, could
avoid future costs by focusing on those individuals who are
susceptible to suffer a deterioration on their health state.
Methods
Data
Data used relate to the population of the county of Baix
Empordà in Catalonia for the period 2004–2007. The
average population was N = 88,858. Natural population
movements and migrations (new arrivals and departures)
were continuously recorded. For our purposes, yearly
counts of individuals were made at the end of each year.
The information was provided by Serveis de Salut
Integrats del Baix Empordà (SSIBE), an integrated health-
care management organisation responsible for providing
public healthcare services, including primary care, specia-
lised care, acute hospitalisations and long-term residential
care. For administration purposes SSIBE runs an inte-
grated patient database with clinical records and individual
information on use of resources and activity for the whole
population [26].
Using the CRG model, individuals were classified into
single, mutually exclusive, and exhaustive categories
according to their clinical findings and demographic
characteristics. The original CRG core health status
classification aggregates individual morbidity histories
into nine categories: (1) Healthya, (2) History of significant
acute disease, (3) Single minor chronic disease, (4) Minor
chronic disease in multiple organ systems, (5) Single
dominant or moderate chronic disease, (6) Significant
chronic disease in multiple organ system, (7) Dominant
chronic disease in three or more organ systems, (8) Dom-
inant and metastatic malignancies and (9) Catastrophic
conditions. However, in order to avoid CRG cells
grouping a small number of individuals, we aggregated
individual morbidity histories into six core health status,
following a classification based on the article of Neff et al.
[27]: E1 Healthy, E2 Significant acute disease, E34 Minor
chronic disease, E56 Significant chronic disease in one or
Table 2 Aggregated clinical risk group categories of
patients at 1/1/2007
Core Health Status Groups %
E1. Healthy 65.45%
E2. Significant acute disease 9.05%
E34. Minor chronic disease 7.43%
E56. Significant chronic disease in one or two organ systems 17.26%
E79. Significant chronic disease in three or more organ systems
- Catastrophic conditions
0.58%
E8. Dominant and metastatic malignancies 0.23%
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three or more organ systems - Catastrophic conditions,
E8 Dominant and metastatic malignancies [28].
Individual morbidity categories (CRG) were generated
every year using all the individual information on diag-
nostics and procedures related to the population. For
example, the system processed 857,385 ICD codes (815,227
diagnostics and 42,158 procedures collected between 1/1/
2007 and 31/12/2007) that were related to the 90,595
individuals included in the study in 2007.
The demographic characteristics and the risk profile
of the population in 2007 are shown in Tables 1 and 2
respectively. Males made up a slightly larger group, and
about 65% of the SSIBE population belonged to the status
Healthy.
Ethics
This study is part of a research on population morbidity
and healthcare expenditures and was carried out using
individual anonymous data provided by SSIBE. The Re-
search Committee of SSIBE authorized the study and the
data transfer protocol.
Morbidity patterns for the lifetime
Individual morbidity patterns for the lifetime were
obtained by assuming they follow a stationary Markov
chain. A Markov chain is defined as a discrete stochastic
process which meets the Markov property. Suppose that
time takes the discrete values t = 1,2, …, n (natural
years in our case), and for any given time, the health
state Xt can take the value xt, from the discrete space
of states xt,1,xt,2,…,xt,m. Since there are six core CRG
health status groups, and death is an additional, absorbing,
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the fundamental assumption is that the health state of
an individual for a specific year depended only on the
health state observed the year before. Such characteristics
correspond to the Markov Chain framework [29-32].
The transition probabilities in the Markov model were
easily inferred because the complete health state sequence
(from 2004 to 2007) was known for the entire population.
Therefore, transition probabilities were obtained by ob-
serving individual status changes for each pair of years
in the study (2004–2005, 2005–2006, 2006–2007) as











were t = 1, 2, …, T are the times of observation, i, j = 1,
2, …, m are the states of the process and nij are the
number of individuals in state j at time t, having state
i at time t-1.
The probability estimates were obtained from the data
according to the formula. Twenty transition matrices
were obtained, considering gender and ten age groups: <
1 year of age, 1–14 years of age, 15–24, 25–34, 35–44,
45–54, 55–64, 65–74, 75–84, ≥ 85.
In the above we have assumed stationarity in the Markov
chain. Consequently, transition probabilities are supposed
to be stationary or homogeneous, i.e. transition matrices
are considered stable, and the probability of moving from
one specific health state to another remains constant over
time. The adequacy of the stationary property was tested
by comparing distances between stationary and temporal
probabilities to the Xi squared distribution with m(m-1)
(T-1) degrees of freedom:
XX h i
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Test results showed how all the probabilities included
in transition matrices were stationary during the period
2004–2007, with the exception of men aged 75–84.
The morbidity evolution was obtained from the Markov
chain structure by combining two simulation strategies:
1. Markov cohort simulation: A cohort of N = 100,000
individuals, evolved from birth to death. The initial
cohort composition followed the morbidity and
gender structure of the 2007 population (0–1 years
of age group). Then, the simulation algorithm
generated a sequence of cycles until the complete
extinction of the cohort. A new cycle in the
simulation reproduced a year of life for the cohort:
individuals which were grouped according to their
gender, age and health state characteristics, changed
their health conditions according to the appropriate
transition probabilities.
2. Monte Carlo simulation: The second simulation
generated random lifetime health histories. The
process started assigning a random health status for
a standard individual. Starting at birth, the
simulation algorithm generated a sequence of cycles
until his death. A new cycle in the simulation
reproduced a new year of life for such individual.
Changes in health status during life were obtained
generating pseudo-random numbers and comparing
them to the transition probabilities. The process was
repeated for N1 = 10,000 females and N2 = 10,000
males. Finally, the result was a collection of
pathways.
These strategies were complementary. The result of
the first simulation was exact, according to the initial
cohort characteristics and the transition matrix of
probabilities. Conversely, depending on the number of
trials, the result of the second simulation may contain
certain bias as a consequence of the use of pseudo-
random numbers. The major advantage of the second
simulation is that it provides measures of variability.
Adding costs to the model
Once the projection of the future population morbidity
was obtained, the next step in the process involved the
evaluation of costs. Depending on the simulation strategy,
a new cycle generated a new number of individuals with
specific age, gender and health status (a new year in
the cohort history) or a new specific individual condition(a new year in the individual health history). Throughout
the process, we evaluated costs for these situations using
average costs adjusted by age, gender and CRG status.
Mean cost estimates corresponded to the SSIBE database
from year 2007.
Table 3 summarizes mean costs by gender and health
status for the whole population in 2007. Mean costs
included primary care, specialised care, acute hospita-
lisations, long-term residential care and pharmaceutical
consumption outside the institution.
The SSIBE costing methodology is a retrospective full-
cost system [33], which combines the bottom-up and
the top-down approaches described in [34]. Therefore,
direct costs (blood transfusions, prostheses, intermediate
products, and pharmaceutical consumption) were directly
attributed to patients from their clinical records using
the bottom-up approach. At the same time, using activity
records and the related unit costs, departmental costs
were apportioned to patients according to the individual
consumption of health services resources (top-down
microcosting approach).
It is important to remember that SSIBE is responsible
for the public provision of first-level healthcare: I.e.
complex care - for example organ transplant, neonatology
or neurosurgery - is systematically referred to complex
hospitals outside the county. External referrals represented
2.2% of the total activity and 17% of the total costs for
SSIBE in 2007 [35]. The main cases of external referrals
included high-complexity hospitalisations, psychiatric
hospitalisation and ambulatory mental health.
Results and discussion
Cohort simulation
The result of the first simulation was a morbidity pro-
jection for a cohort of N = 100,000 individuals. Since
the time horizon was over the whole life cycle, people
developed from birth to death. We obtained the prob-
ability of having a specific health state in the future.
Figures 1 and 2 show the lifetime burden of morbidity
by gender at any age.
The first years of life were particularly complex. Figures 1
and 2 above show abrupt probability jumps due to age
group construction (< 1 year of age, 1–14 years of age).
Approximately 96% of the initial cohort was classified
as healthy individuals. Nevertheless, Figures 1 and 2 show
a serious peak of acute processes related to different health
problems in the first year of life.
Gender differences were remarkable through life. In
general, with the exception of the early age groups (<
1 year of age, 1–14 years of age), the burden of morbid-
ity was higher for females. Women clearly had a higher
probability of suffering an acute process as a consequence
of childbearing age (14–40 years of age)b. Moreover,
the healthy status area was proportionally reduced (see
Table 3 Cost (euros) by health status
Core Health Status Groups Mean cost
Females Males
E1. Healthy 324.16 227.42
E2. Significant acute disease 1,692.67 1,195.57
E34. Minor chronic disease 1,069.41 936.65
E56. Significant chronic disease in one or two organ systems 2,739.67 2,334.04
E79. Significant chronic disease in three or more organ systems - Catastrophic conditions 11,095.93 10,113.71
E8. Dominant and metastatic malignancies 5,617.47 5,519.98
Year 2007.
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improve for women, the healthy status area continued
to be narrower than for men, with an increase in the main
chronic categories. Conversely, the yearly probabilities
of having a healthy life were higher for males above
14 years of age. At the same time they experienced a
proportional reduction in the probabilities of falling
into a chronic category.
Table 4 shows expected years at birth by gender and
health status.
Life expectancy at birth obtained from the model was
83.79 years for females, approximately 5.38 years longer
than for males (78.41), and consistent with official public
estimates for 2007 [36]. Healthy life expectancy at birth
for females was 46.99, lower than for males (50.22).
Females also spent 28.41 years of life suffering from
some type of chronic disease, a longer period than males
(21.9). Finally, males were more likely to fall into the
highest morbidity groups: ‘E79 Significant chronic disease
in three or more organ systems - dominant and metastatic
malignancies’ and ‘E8 Catastrophic conditions’. However,
a small number of individuals were included in both





















Figure 1 Cohort simulation - Females. E1: Healthy. E2: Significant acute
one or two organ systems. E79: Significant chronic disease in three or more
malignancies. E0*: Death (Added as the absorbing state).population included in categories E79 or E8 remained
below 1%.
A projection of costs was obtained by combining the
cohort simulation results with SSIBE costs. Different
summations of the Markov Chain generated different
results: First, after aggregating costs for a specific year
in the projection, we obtained the mean cost by gender
(Figure 3). Second, after aggregating the process through
life, we obtained the mean lifetime cost for a typical indi-
vidual. Mean lifetime costs for women was €111,935.96, a
third more than for men, at €81,565.67. The relationship
between mean costs by gender is consistent with the
results from different studies with different populations, in
the sense that women use of healthcare resources was a
third more than men throughout their lives [3,15].
Monte Carlo simulation
A collection of pathways were generated from the second
simulation. N1 = 10,000 for women and N2 = 10,000 for
men. Each pathway was randomly obtained from observed
transitions and represented the lifetime morbidity history
for a typical individual. Standard individuals received


















disease. E34: Minor chronic disease. E56: Significant chronic disease in





































Figure 2 Cohort simulation - Males. E1: Healthy. E2: Significant acute disease. E34: Minor chronic disease. E56: Significant chronic disease in one
or two organ systems. E79: Significant chronic disease in three or more organ systems - Catastrophic conditions. E8: Dominant and metastatic
malignancies. E0*: Death (Added as the absorbing state).
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the first age group (< 1 year of age).
The distribution function of the random variable life-
time healthcare costs was drawn from the second simu-
lation. Since we used mean costs by gender, sex and
health status, these cumulative frequencies represented
primarily the variability of health transitions among
individuals. Table 5 shows the main statistics.
The mean lifetime healthcare cost obtained from the
second simulation was €111,255.10 for women and
€81,495.67 for men. Differences in cost averages be-
tween both simulation strategies pointed out the bias of
the individual simulation. However, such differences
remained below 0.7%.
On the other hand, the distribution of costs of both
genders was right-skewed. The higher variance and
kurtosis for women can be interpreted as more variability
and heavier tails for the distribution of probability, which
expressed the heterogeneity of female morbidity (Figures 4
and 5). In other words, the burden of morbidity generated
higher costs for women, with more differences among
individuals and more individuals with large costs. SuchTable 4 Expected years of life at birth by health status (indiv
Core health status groups
E1. Healthy
E2. Significant acute disease
E34. Minor chronic disease
E56. Significant chronic disease in one or two organ systems
E79. Significant chronic disease in three or more organ systems - Catastrophi
E8. Dominant and metastatic malignancies
Totaldifferences in average costs between genders are main-
tained for percentiles 25th, 50th and 75th.
Implications
Consistency with other lifetime cost studies and official
life expectancy reports imply that the results obtained
are reasonable [3,15,36]. But, how can these results be
converted in gains in effectiveness and cost reductions?
Chronic disease management strategies are based on the
stratification of the population according to their risks
[4]. Introducing the longitudinal perspective, we observed
how individual stocks of health were progressively lost
during life, by the impact of acute episodes and by the
advance of chronic diseases. Therefore, such information
on health transitions could be used to design specific
measures for different segments of the population. E.g.
healthy individuals or people with complex healthcare
needs require distinct measures for preventing health
deterioration.
Healthy individuals represent an important share of the
population at any age. Considering results from Tables 1,
2 and 3, it is important to see how the amount ofidual simulation)
Females Males
Mean SD Min Max Mean SD Min Max
- 46.99 7.26 2 80 + 50.22 7.25 17 81
+ 8.39 3.37 0 24 - 6.30 2.92 0 20
+ 7.74 3.63 0 26 - 4.37 2.69 0 20
+ 19.96 8.40 0 56 - 16.36 8.31 0 61
c conditions 0.52 1.09 0 13 0.87 1.65 0 20
0.19 0.64 0 9 0.29 0.68 0 8






















Figure 3 Yearly mean cost (€). Females: Continuous line. Males: Dotted line.
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exceeded the amount spent on individuals with acute
hospitalisationsa. Hughes et al. obtained a similar result
using a sample of 1.3 million beneficiaries from Medicare,
Medicaid and private insurance [19]. Therefore, healthcare
planners should explore specific programs for healthy
individuals. For example, promoting healthy lifestyle
education, personal responsibility on health or risk pre-
vention in the workplace. Moreover, from a lifetime
perspective, reducing transitions from health to worst
conditions could generate large health gains for the
population and large resource savings for the health-
care system.
According to Figures 1, 2 and 3, from the age group
35–44, the level of mean costs by gender for all ages is
strongly related to the amount of individuals with more
than one chronic disease. Despite of other effects, for
example the amount of individuals with acute hospitali-
sations. In fact, an important number of individuals suffer
a significant chronic disease in one or two organ systems
many years during their life (19.96 years females, 16.36
males). Moreover, a small number of patients with a
significant chronic disease in three or more organ systems
are associated with a significant level of healthcareTable 5 Distribution function of lifetime healthcare cost
Females Males











75 131,655.66 102,511.78expenditures. Regarding the high impact of chronic disease
during life, chronic disease management strategies offer
a good opportunity to gain efficiency by providing cost-
effective care to patients with complex care needs [4,5].
From a gender perspective, a higher lifetime healthcare
cost for women - a third more than men throughout their
lives - is a consequence of a higher life expectancy and a
higher acute and chronic disease prevalence. Gender
specific measures have a high margin for gaining efficiency.
Finally, specific interventions, including those affecting
healthy population, should be implemented following
cost-effectiveness standards.Model limitations and future research
Although this article is not method-oriented, in the
sense that we did not make any essential contribution to
the Markov literature, some questions on the fundamental
assumptions must be considered.
A first concern is if the Markov property is suitable for
describing the individual morbidity development. The
fundamental Markov property establishes that the health
status of an individual within a specific year depends on
the health status the year before. Therefore, did the last
twelve month sequence of ICD codes completely describe
individual health histories? For a number of reasons,
significant ICD codes could be missing in the latest
clinical records. Consequently, the CRG classification
can slightly underestimate health status, especially for
health status E34 and E56a. It is important to be careful at
this point: CRG categories describe individual behaviour
in relation to the use of health services and must be con-
sidered an approximation to the health state of individuals.
Moreover, due to the unexpected nature of a considerable
part of health related events, the maximum predictive
capacity for any risk-adjustment system is limited. For
risk adjustment purposes, the CRG manual recommends
collecting codes for a period of between six months
and two years [28]. However, Hughes et al. did not find
significant increases in the amount of variance explained by















Figure 4 Lifetime healthcare cost distribution (€) - Females.
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chain is stationary. A stationary process is independent
from the point in time in which it is observed. In other
words, process parameters - transition probabilities in our
model - are considered constant over time. According
to the results, with the exception of men aged 75–84,
transition probabilities are stationary in the period 2004–
2007. However, is it reasonable to assume stationary
probabilities in the long run? Obviously the answer is
no. During the period 1998–2007 life expectancy at











Figure 5 Lifetime healthcare cost distribution (€) - Males.[36]. Therefore, transitions to death are not stationary.
Moreover, the effect on transitions between health states
is unknown. Recent studies suggest that changes in prac-
tice and new technologies have produced a demographic
change, increasing life expectancy and improving the
quality of life. The consequence is a change in patient
profiles with an increase in the prevalence of chronic
conditions and polypathology. Thorpe and Howard
found evidence of the increased prevalence for the top
ten chronic conditions (Heart disease, Mental disorders,
Trauma, Arthritis, Hypertension, Cancer, Diabetes, Pul-Cost
400000,00300000,000000,00
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disease) for US Medicare beneficiaries from 1987 to 2002
[37]. Other works show how the number of patients
with different combinations of chronic conditions is
expected to increase in the future [38]. Moreover, the
increasing prevalence of chronic disease among the
near-elderly forecasts a gradual increase in morbidity
among the elderly [22].
Individual chronic conditions and polypathology have
been included in the model. However, the main limitation
of the study is to build a morbidity projection from a
fixed transition pattern corresponding to the period
2004–2007. More research on transition distributions
and essentially large series of data are needed in order
to break through the stationary assumption.
Costs limitations and future research
Our model includes mean full costs from SSIBE cor-
responding to the year 2007. Such mean costs were
aggregated by health status, age group and gender.
Therefore, according to the CRG literature, the amount
of variance explained by the model in respect to the
potential realisations of costs was around 20% [19,33].
Since our article is devoted to introducing chronic
conditions into lifetime healthcare costs estimates, other
fundamental assumptions were deliberately assumed in
their simplest form. However, there is a clear evidence of
the importance of economic-related assumptions on
forecasting exercises: the proportion of gross domestic
product (GDP) spent on healthcare has a significant influ-
ence in forecasts [39]. At the same time, different studies
reported the huge impact of innovation in future spending
[22,40]. Moreover, the impact of changes in practices in
future spending is estimated to be 3.8 times larger than
the impact of demographic changes (e.g., ageing of the
population) [41]. Consequently, more research is required
in the area of costs as well. For example, the methodology
of the Age Working Group considered aggregate scenarios
on the future evolution of health expenditures [42].
Such scenarios were built from projections, assuming
that unit costs evolve at the same rate as GDP per
capita or per worker.
Due to the high concentration of costs in the last period
of life, some authors considered health care expenditures
to be a function of remaining life [43] or proximity to
death instead of calendar age: the so-called red herring
hypothesis [24]. However such studies are focused on
an ageing population. Since the scope of our work is
the whole life cycle, and chronic conditions and multi-
morbidity increase from early ages [44], calendar age was
used instead of remaining life. Moreover, establishing
current health conditional on the future (remaining life)
would collide with the Markov property: health in the
future (next year) is based on current health.This study is limited in other ways as well. A larger
population would allow us to describe individual morbid-
ity and transitions under a more detailed scale: following
the CRG hierarchy, ACRG3 (46 groups), ACRG2 (176
groups), ACRG1 (441 groups) or CRG (1,099 groups).
Nevertheless, we are convinced that the six core health
status groups describe chronic conditions and multi-
morbidity patterns reasonably well.Conclusions
Future morbidity and whole population costs can be rea-
sonably predicted, combining stochastic microsimulation
with a morbidity classification system. Potential ways of
efficiency arose by introducing a time perspective to
chronic disease management. The target of such new
measures are people with chronic conditions and mul-
timorbidity. Nevertheless, healthy individuals require
specific policies.
Our model is just a first step. Considering stationary
transitions and costs is a serious limitation. New sources
of evidence on health state transitions and more sophisti-
cated assumptions about future costs are needed.Endnotes
aAccording to the original definitions from the CRG
manual [28], a healthy status is defined as follows: “A
healthy status is identified by the absence of any primary
chronic disease or significant acute episode diagnosis
categories or episode procedure category. These indi-
viduals may have minor acute diagnosis present (e.g.,
upper respiratory infection, minor fractures, hernia,
etc.) but are otherwise healthy. The healthy status also
includes individuals who had no medical care encoun-
ters. CRGs are assigned hierarchically starting with
most serious status, catastrophic, and going to the least
serious, healthy Status 1 in the most recent six-month
period. It is possible that in any population this includes a
subset of individuals with chronic diseases who did not
access the medical care system during the time period
used to assign the CRG”.
bIn the year 2007 CRG categories 2070 Pregnancy
without Childbirth with Other Significant Illness, 2080
Pregnancy and Childbirth with Other Significant Illness
and 2090 Pregnancy with Major Complications and Other
Significant Illness represented a 20% of acute processes for
women included in the age group 15–24. Percentage
values increased to 41% and 21% for women included in
the age groups 25–34 and 35–44 respectively.
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